Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Vertex Pharmaceuticals Inc. closed $106.51 short of its 52-week high ($519.88), which the company reached on November 8th.

Net Margin: Vertex Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 37.71%, the company demonstrates strong profitability and effective cost management.

The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...

Trikafta is Vertex Pharmaceuticals' biggest moneymaker ... insurance reimbursement and rebates — while Alyftrek will cost $370,269, Abrahams said. Alyftrek is a once-daily pill.

Vertex Pharmaceuticals and Orna Therapeutics announce a $4 billion collaboration to develop in vivo gene editing therapies ...